<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36719379</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e157272</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI157272</ELocationID><Abstract><AbstractText>Signaling driven by nucleic acid sensors participates in interferonopathy-mediated autoimmune diseases. NLRP12, a pyrin-containing NLR protein, is a negative regulator of innate immune activation and type I interferon (IFN-I) production. Peripheral blood mononuclear cells (PBMCs) derived from systemic lupus erythematosus (SLE) patients expressed lower levels of NLRP12, with an inverse correlation with IFNA expression and high disease activity. NLRP12 expression was transcriptionally suppressed by runt-related transcription factor 1-dependent (RUNX1-dependent) epigenetic regulation under IFN-I treatment, which enhanced a negative feedback loop between low NLRP12 expression and IFN-I production. Reduced NLRP12 protein levels in SLE monocytes was linked to spontaneous activation of innate immune signaling and hyperresponsiveness to nucleic acid stimulations. Pristane-treated Nlrp12-/- mice exhibited augmented inflammation and immune responses; and substantial lymphoid hypertrophy was characterized in NLRP12-deficient lupus-prone mice. NLRP12 deficiency mediated the increase of autoantibody production, intensive glomerular IgG deposition, monocyte recruitment, and the deterioration of kidney function. These were bound in an IFN-I signature-dependent manner in the mouse models. Collectively, we reveal a remarkable link between low NLRP12 expression and lupus progression, which suggests the impact of NLRP12 on homeostasis and immune resilience.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Yen-Po</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy, Immunology and Rheumatology, Department of Medicine, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Holistic and Multidisciplinary Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Fang-Yu</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming-Han</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Division of Allergy, Immunology and Rheumatology, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdulkareem</LastName><ForeName>Babamale Olarewaju</ForeName><Initials>BO</Initials><AffiliationInfo><Affiliation>Taiwan International Graduate Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Se-Yi</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chung-Shan Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Wen-Ting</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Pei-Ching</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>I-Chun</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Pin-Hsuan</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chien-Sheng</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chang-Youh</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Division of Allergy, Immunology and Rheumatology, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Szu-Ting</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taiwan International Graduate Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Progression Research Center, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C553199">NLRP12 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009696">Nucleic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Clin Invest. 2023 May 1;133(9):</RefSource><PMID Version="1">37115700</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009696" MajorTopicYN="Y">Nucleic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Innate immunity</Keyword><Keyword MajorTopicYN="N">Lupus</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> The authors have declared that no conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36719379</ArticleId><ArticleId IdType="pmc">PMC9888378</ArticleId><ArticleId IdType="doi">10.1172/JCI157272</ArticleId><ArticleId IdType="pii">157272</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Merrill JT, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222&#x2013;233. doi: 10.1002/art.27233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat FJ, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202(8):1131&#x2013;1139. doi: 10.1084/jem.20050914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050914</ArticleId><ArticleId IdType="pmc">PMC2213213</ArticleId><ArticleId IdType="pubmed">16230478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, et al. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis. 2018;77(10):1507&#x2013;1515. doi: 10.1136/annrheumdis-2018-212988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-212988</ArticleId><ArticleId IdType="pmc">PMC6161667</ArticleId><ArticleId IdType="pubmed">29945921</ArticleId></ArticleIdList></Reference><Reference><Citation>Celhar T, et al. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res. 2012;53(1-3):58&#x2013;77. doi: 10.1007/s12026-012-8270-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-012-8270-1</ArticleId><ArticleId IdType="pubmed">22434514</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisitkun P, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312(5780):1669&#x2013;1672. doi: 10.1126/science.1124978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1124978</ArticleId><ArticleId IdType="pubmed">16709748</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese E, et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 2008;58(4):1107&#x2013;1115. doi: 10.1002/art.23407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23407</ArticleId><ArticleId IdType="pubmed">18383384</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen SR, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25(3):417&#x2013;428. doi: 10.1016/j.immuni.2006.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.07.013</ArticleId><ArticleId IdType="pubmed">16973389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao D, et al. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci U S A. 2015;112(42):E5699&#x2013;E5705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620884</ArticleId><ArticleId IdType="pubmed">26371324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn J, et al. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A. 2012;109(47):19386&#x2013;19391. doi: 10.1073/pnas.1215006109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1215006109</ArticleId><ArticleId IdType="pmc">PMC3511090</ArticleId><ArticleId IdType="pubmed">23132945</ArticleId></ArticleIdList></Reference><Reference><Citation>Means TK, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005;115(2):407&#x2013;417. doi: 10.1172/JCI23025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23025</ArticleId><ArticleId IdType="pmc">PMC544604</ArticleId><ArticleId IdType="pubmed">15668740</ArticleId></ArticleIdList></Reference><Reference><Citation>Stetson DB, et al. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134(4):587&#x2013;598. doi: 10.1016/j.cell.2008.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.06.032</ArticleId><ArticleId IdType="pmc">PMC2626626</ArticleId><ArticleId IdType="pubmed">18724932</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610&#x2013;2615. doi: 10.1073/pnas.0337679100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294(5546):1540&#x2013;1543. doi: 10.1126/science.1064890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1064890</ArticleId><ArticleId IdType="pubmed">11711679</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo GS, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3143837</ArticleId><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle CE, et al. Network analysis of associations between serum interferon-&#x3b1; activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044&#x2013;1053. doi: 10.1002/art.30187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30187</ArticleId><ArticleId IdType="pmc">PMC3068224</ArticleId><ArticleId IdType="pubmed">21162028</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen IC, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-&#x3ba;B signaling. Immunity. 2012;36(5):742&#x2013;754. doi: 10.1016/j.immuni.2012.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.03.012</ArticleId><ArticleId IdType="pmc">PMC3658309</ArticleId><ArticleId IdType="pubmed">22503542</ArticleId></ArticleIdList></Reference><Reference><Citation>Truax AD, et al. The inhibitory innate immune sensor NLRP12 maintains a threshold against obesity by regulating gut microbiota homeostasis. Cell Host Microbe. 2018;24(3):364&#x2013;378. doi: 10.1016/j.chom.2018.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.08.009</ArticleId><ArticleId IdType="pmc">PMC6161752</ArticleId><ArticleId IdType="pubmed">30212649</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ST, et al. NLRP12 regulates anti-viral RIG-I activation via interaction with TRIM25. Cell Host Microbe. 2019;25(4):602&#x2013;616. doi: 10.1016/j.chom.2019.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2019.02.013</ArticleId><ArticleId IdType="pmc">PMC6459718</ArticleId><ArticleId IdType="pubmed">30902577</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SS, et al. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol Int. 2019;39(11):1937&#x2013;1944. doi: 10.1007/s00296-019-04445-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04445-y</ArticleId><ArticleId IdType="pubmed">31552434</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, et al. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyers S, et al. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol. 1993;13(10):6336&#x2013;6345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC364692</ArticleId><ArticleId IdType="pubmed">8413232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffries MA. Epigenetic editing: how cutting-edge targeted epigenetic modification might provide novel avenues for autoimmune disease therapy. Clin Immunol. 2018;196:49&#x2013;58. doi: 10.1016/j.clim.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.02.001</ArticleId><ArticleId IdType="pmc">PMC6078821</ArticleId><ArticleId IdType="pubmed">29421443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674&#x2013;678. doi: 10.1038/nature07317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07317</ArticleId><ArticleId IdType="pmc">PMC2804933</ArticleId><ArticleId IdType="pubmed">18724357</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16(1):3&#x2013;9. doi: 10.1016/j.smim.2003.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2003.10.003</ArticleId><ArticleId IdType="pubmed">14751757</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107. doi: 10.1186/s13075-019-1878-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves WH, et al. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30(9):455&#x2013;464. doi: 10.1016/j.it.2009.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2009.06.003</ArticleId><ArticleId IdType="pmc">PMC2746238</ArticleId><ArticleId IdType="pubmed">19699150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PY, et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol. 2009;175(5):2023&#x2013;2033. doi: 10.2353/ajpath.2009.090328.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2009.090328</ArticleId><ArticleId IdType="pmc">PMC2774066</ArticleId><ArticleId IdType="pubmed">19808647</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirley JL, et al. Type I IFN sensing by cDCs and CD4+ T cell help are both requisite for cross-priming of AAV capsid-specific CD8+ T cells. Mol Ther. 2020;28(3):758&#x2013;770. doi: 10.1016/j.ymthe.2019.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.11.011</ArticleId><ArticleId IdType="pmc">PMC7054715</ArticleId><ArticleId IdType="pubmed">31780366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose J, et al. Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. J Clin Invest. 2019;129(6):2251&#x2013;2265. doi: 10.1172/JCI125116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI125116</ArticleId><ArticleId IdType="pmc">PMC6546471</ArticleId><ArticleId IdType="pubmed">31033479</ArticleId></ArticleIdList></Reference><Reference><Citation>Olaru F, et al. Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis. JCI Insight. 2018;3(11):96492. doi: 10.1172/jci.insight.96492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.96492</ArticleId><ArticleId IdType="pmc">PMC6124405</ArticleId><ArticleId IdType="pubmed">29875315</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa F, et al. Inflammatory monocyte-derived dendritic cells mediate autoimmunity in murine model of systemic lupus erythematosus. J Transl Autoimmun. 2020;3:100060. doi: 10.1016/j.jtauto.2020.100060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2020.100060</ArticleId><ArticleId IdType="pmc">PMC7388367</ArticleId><ArticleId IdType="pubmed">32743540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cros J, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375&#x2013;386. doi: 10.1016/j.immuni.2010.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.08.012</ArticleId><ArticleId IdType="pmc">PMC3063338</ArticleId><ArticleId IdType="pubmed">20832340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto S, et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis. 2007;50(1):47&#x2013;58. doi: 10.1053/j.ajkd.2007.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2007.04.012</ArticleId><ArticleId IdType="pubmed">17591524</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel RR, et al. Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Proc Natl Acad Sci U S A. 2020;117(10):5409&#x2013;5419. doi: 10.1073/pnas.1916897117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1916897117</ArticleId><ArticleId IdType="pmc">PMC7071891</ArticleId><ArticleId IdType="pubmed">32094169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, et al. IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol. 2021;12:676082. doi: 10.3389/fimmu.2021.676082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676082</ArticleId><ArticleId IdType="pmc">PMC8093624</ArticleId><ArticleId IdType="pubmed">33959133</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CJ, et al. Triggering receptor expressed on myeloid cells-1 (trem-1) deficiency augments BAFF production to promote lupus progression. J Autoimmun. 2017;78:92&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">28089248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinjyo I, et al. Cutting edge: lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin. J Immunol. 2010;185(12):7151&#x2013;7155. doi: 10.4049/jimmunol.1003193.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1003193</ArticleId><ArticleId IdType="pmc">PMC2997140</ArticleId><ArticleId IdType="pubmed">21076068</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinet V, et al. Type I interferons regulate eomesodermin expression and the development of unconventional memory CD8(+) T cells. Nat Commun. 2015;6:7089. doi: 10.1038/ncomms8089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8089</ArticleId><ArticleId IdType="pmc">PMC4432629</ArticleId><ArticleId IdType="pubmed">25953241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay EM, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">8210301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol. 2021;31(1):20&#x2013;28. doi: 10.1080/14397595.2020.1775928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1775928</ArticleId><ArticleId IdType="pubmed">32475188</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, et al. Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376&#x2013;386. doi: 10.1002/art.39962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai L, et al. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther. 2021;23(1):29. doi: 10.1186/s13075-021-02414-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02414-0</ArticleId><ArticleId IdType="pmc">PMC7811214</ArticleId><ArticleId IdType="pubmed">33451338</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>